Lovenox Dosing in High-Risk Pregnant Women
This study is looking at how well Lovenox (a medication to prevent blood clots) works in pregnant women who need it. Pregnancy increases the risk of blood clots, and previous studies suggest that the usual Lovenox dosing might not be enough for many pregnant women. This study will give Lovenox three times a day and measure the levels of the drug in your blood (Factor Xa levels) 4 hours after each injection. This will help researchers understand if this dosing schedule provides adequate protection. You may be able to join if you are 18 or older, are pregnant with one baby, and need Lovenox. The study is currently unclear about its recruitment status.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 12 women.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, Factor Xa levels, is measured 4 hours after injection. The overall follow-up duration is not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Afshan Hameed · PRINCIPAL_INVESTIGATOR · University of California, Irvine
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Factor Xa levels4 hours after injection